Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies

BACKGROUND: We report on the activity of the combination of epirubicin and docetaxel given in neoadjuvant setting for 4 and 8 cycles respectively in 2 successive series of patients with large operable or locally advanced, hormone receptor positive, HER-2 negative breast cancer. PATIENTS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuzi, Alessandro, Lombardi, Davide, Crivellari, Diana, Militello, Loredana, Perin, Tiziana, La Grassa, Manuela, Massarut, Samuele, Veronesi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Versita, Warsaw 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573835/
https://www.ncbi.nlm.nih.gov/pubmed/23450278
http://dx.doi.org/10.2478/raon-2013-0012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573835/
https://www.ncbi.nlm.nih.gov/pubmed/23450278
http://dx.doi.org/10.2478/raon-2013-0012

Ejemplares similares